MiR-380 inhibits the proliferation and invasion of cholangiocarcinoma cells by silencing LIS1
Cancer Cell International,
Abstract Background The objective of this study was to determine the role and regulatory mechanism of miR-380 in…
Abstract Background The objective of this study was to determine the role and regulatory mechanism of miR-380 in…
Follow Summary Relay Therapeutics is a biotech company focused on developing small molecule inhibitors for cancer treatment.
GlobeNewswire 2023-10-16 MONTREAL, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-Americ…
MONTREAL, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty…
MONTREAL, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty…
MONTREAL, Oct. 16, 2023 Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company…
Loading...Loading...Loading... MONTREAL, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., GUD ("Knight") a pan-America…
MONTREAL, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty…
MONTREAL, 10 de outubro de 2023 /PRNewswire/ -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), uma empresa pan-americana (ex-EU…
GlobeNewswire 2023-10-10 MONTREAL, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-Americ…
MONTRÉAL, 10 oct. 2023 (GLOBE NEWSWIRE) -- Thérapeutique Knight inc. (TSX : GUD) («?Knight?» ou la «?Société?»), société…
MONTREAL, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty…
MONTREAL, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty…
MONTREAL, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty…
MONTREAL, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., GUD ("Knight") a pan-American (ex-USA) specialty…
MONTREAL, Oct. 10, 2023 Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company…
MONTRÉAL, 10 oct. 2023 (GLOBE NEWSWIRE) -- Thérapeutique Knight inc. (TSX : GUD) (« Knight » ou la « Société »), société…
MONTREAL, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty…
Follow Summary Last month, ZYME presented strong data in HER2+ BTC. Its Jazz collaboration has given it access to a lot of funds.
A survival benefit was elicited with the use of pemigatinib when used for patients with previously treated advanced…
Khaled W. Kabbara, MD, and colleagues, research treatment options for cholangiocarcinoma.
SAN FRANCISCO and SUZHOU, China, Jan. 24, 2022 /PRNewswire/ -- Innovent Biologics, Inc.
24-Jan-2022 Intellasia | PR Newswire Asia | 2:22 PM SAN FRANCISCO and SUZHOU, China, Jan.
SAN FRANCISCO and SUZHOU, China, Jan. 24, 2022 /PRNewswire/ Innovent Biologics, Inc.
SAN FRANCISCO and SUZHOU, China, Jan. 24, 2022 /PRNewswire/ -- Innovent Biologics, Inc.
SAN FRANCISCO and SUZHOU, China, Jan. 24, 2022 /PRNewswire/ -- Innovent Biologics, Inc.
SAN FRANCISCO and SUZHOU, China, Jan. 24, 2022 /PRNewswire/ -- Innovent Biologics, Inc.
SAN FRANCISCO and SUZHOU, China, Jan. 24, 2022 /PRNewswire/ -- Innovent Biologics, Inc.
SAN FRANCISCO and SUZHOU, China, Jan. 24, 2022 /PRNewswire/ -- Innovent Biologics, Inc.
SAN FRANCISCO and SUZHOU, China, Jan. 24, 2022 /PRNewswire/ Innovent Biologics, Inc.
SAN FRANCISCO and SUZHOU, China, Jan. 24, 2022 /PRNewswire/ -- Innovent Biologics, Inc.
Innovent Announces the Approval of Pemazyre® (pemigatinib) in Hong Kong Market for the Treatment of Adults With Locally…
SAN FRANCISCO and SUZHOU, China, Jan. 24, 2022 /PRNewswire/ -- Innovent Biologics, Inc.
SAN FRANCISCO and SUZHOU, China, Jan. 24, 2022 /PRNewswire/ -- Innovent Biologics, Inc.
SAN FRANCISCO and SUZHOU, China, Jan. 24, 2022 /PRNewswire/ -- Innovent Biologics, Inc.
SAN FRANCISCO and SUZHOU, China, Jan. 24, 2022 /PRNewswire/ -- Innovent Biologics, Inc.
SAN FRANCISCO and SUZHOU, China, Jan. 24, 2022 /PRNewswire/ -- Innovent Biologics, Inc.
SAN FRANCISCO and SUZHOU, China, Jan. 24, 2022 /PRNewswire/ -- Innovent Biologics, Inc.
SAN FRANCISCO and SUZHOU, China, Jan. 24, 2022 /PRNewswire/ -- Innovent Biologics, Inc.
SAN FRANCISCO and SUZHOU, China, Jan. 24, 2022 /PRNewswire/ -- Innovent Biologics, Inc.
SAN FRANCISCO and SUZHOU, China, Jan. 24, 2022 /PRNewswire/ -- Innovent Biologics, Inc.
美國舊金山和中國蘇州2022年1月24日 /美通社/ -- 信達生物製藥集團(香港聯交所股票代碼:01801),一家致力於研發、生產和銷售用於治療腫瘤、代謝疾病、自身免疫等重大疾病的創新藥物的生物製藥公司,今日宣佈達伯坦(pemigatinib)獲得香港特別…
SAN FRANCISCO and SUZHOU, China, Jan. 24, 2022 /PRNewswire/ -- Innovent Biologics, Inc.
SAN FRANCISCO and SUZHOU, China, Jan. 24, 2022 /PRNewswire/ -- Innovent Biologics, Inc.
SAN FRANCISCO and SUZHOU, China, Jan. 24, 2022 /PRNewswire/ --Innovent Biologics (Innovent) (HKEX: 01801), a world-class…
Next-Generation Sequencing Utilizing Tumor Tissue and/or Blood The identification of actionable genomic alterations in tumors…
Single-agent pemigatinib is being compared with gemcitabine plus cisplatin in patients with unresectable and/or metastatic…
SAN FRANCISCO and SUZHOU, China, June 21, 2021 /PRNewswire/ -- Innovent Biologics, Inc.
SAN FRANCISCO and SUZHOU, China, June 21, 2021 /PRNewswire/ -- Innovent Biologics Inc.
SAN FRANCISCO and SUZHOU, China, June 22, 2021 /PRNewswire/ -- Innovent Biologics, Inc.
SAN FRANCISCO and SUZHOU, China, June 21, 2021 /PRNewswire/ -- Innovent Biologics, Inc.
SAN FRANCISCO and SUZHOU, China, June 21, 2021 /PRNewswire/ -- Innovent Biologics, Inc.
SAN FRANCISCO and SUZHOU, China, June 21, 2021 /PRNewswire/ -- Innovent Biologics, Inc.
SAN FRANCISCO and SUZHOU, China, June 22, 2021 /PRNewswire/ -- Innovent Biologics, Inc.
SAN FRANCISCO and SUZHOU, China, June 21, 2021 /PRNewswire/ -- Innovent Biologics, Inc.
SAN FRANCISCO and SUZHOU, China, June 21, 2021 /PRNewswire/ -- Innovent Biologics, Inc.
SAN FRANCISCO and SUZHOU, China, June 21, 2021 /PRNewswire/ -- Innovent Biologics, Inc.
SAN FRANCISCO and SUZHOU, China, June 21, 2021 /PRNewswire/ -- Innovent Biologics, Inc.
SAN FRANCISCO and SUZHOU, China, June 21, 2021 /PRNewswire/ -- Innovent Biologics, Inc.
SAN FRANCISCO and SUZHOU, China, June 22, 2021 /PRNewswire/ -- Innovent Biologics, Inc.
Innovent Announces the Approval of Pemazyre® (pemigatinib) in Taiwan Market for the Treatment of Adults with Previously Treated…
SAN FRANCISCO and SUZHOU, China, June 21, 2021 /PRNewswire/ Innovent Biologics, Inc.
SAN FRANCISCO and SUZHOU, China, June 21, 2021 /PRNewswire/ -- Innovent Biologics, Inc.
The highly heterogeneous nature of cholangiocarcinoma at the genomic, epigenetic, and molecular levels has led to the…
Biliary tract cancers are an aggressive group of malignancies that historically have been very challenging to treat because of…
The Japanese Ministry of Health, Labour, and Welfare (MHLW) has approved pemigatinib (Pemazyre) for the treatment of patients…
A major barrier to routine genomic profiling of tumors in patients with biliary tract cancer (BTC) is the lack of adequate…
The European Medicine Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended conditional marketing…
The FDA has approved FoundationOne CDx as the registrational companion diagnostic for pemigatinib (Pemazyre), which the agency…
Un nuovo farmaco sperimentale, pemigatinib, ha mostrato un buon potenziale come trattamento per i pazienti con…
Ghassan K. Abou-Alfa, MD Findings from the phase II FIGHT-202 study of pemigatinib in patients with previously treated, locally…